source
- Sellas cancer vaccine cuts death risk by 41% in late-stage AML trialSellas Life Sciences announced results from its Phase 3 REGAL trial evaluating an off‑the‑shelf cancer vaccine in patients with acute myeloid leukemia (AML). The study enrolled 126 individuals who…
- FDA approves Roche's new breast cancer drug, poised to become its top-selling productThe U.S. Food and Drug Administration has granted approval to a new breast cancer therapy developed by Roche. This clearance paves the way for the drug's market launch. Roche says the medication c…